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Vasomotor Function After
Paclitaxel-Coated Balloon Post-Dilation in
Porcine Coronary Stent Model
Takamitsu Nakamura, MD, PHD,* Brigitta C. Brott, MD,† Irena Brants, DVM,*
Deepal Panchal, MS,* Jinsheng Li, MD, PHD,* Jack P. Chen, MD,*
Spencer B. King III, MD,* Nicolas Chronos, MD,* Dongming Hou, MD, PHD*
tlanta, Georgia; and Birmingham, Alabama
Objectives The purpose of this study was to evaluate endothelial function after post-dilation of
bare-metal stents with paclitaxel-coated balloons (PCB) or non–drug-coated balloons (non-DCB) in a
porcine model.
Background DCB are an attractive alternative to drug-eluting stents because they provide short
duration of drug exposure, while potentially inhibiting in-stent restenosis. Drug-eluting stents are
associated with impaired endothelial function. It is unknown whether this abnormal vasomotor func-
tion is mitigated by reduced duration of drug exposure.
Methods Thirteen pigs underwent bare-metal stent implantation (arteries, n  30), followed by
post-dilation with either PCB (SeQuent Please, B. Braun Melsungen AG, Berlin, Germany) (n  17) or
non-DCB (n  13). Five pigs with unstented arteries (n  14) were controls. Coronary vasomotion
was assessed 1 month after stent implantation, using acetylcholine (Ach) and nitroglycerin. Measure-
ments were obtained for distal segments.
Results Angiographic late loss and histological area stenosis were similar between PCB and non-
DCB. However, the percentage of diameter change in response to Ach was diminished with PCB
(p  0.05), when compared with either non-DCB or naive arteries. There was no difference between
non-DCB and naive arteries. Inﬂammatory score and intramural ﬁbrin grading were signiﬁcantly
greater in PCB than non-DCB (p  0.05). Additionally, inﬂammatory cell inﬁltration in the stented
segments correlated with the degree of percentage of diameter change in response to Ach, at distal
regions.
Conclusions Post-dilation of bare-metal stents with PCB was associated with impaired vasodilatory
response to Ach distal to the treated segments. Vasodilatory response after post-dilation with non-
DCB was similar to control arteries. (J Am Coll Cardiol Intv 2011;4:247–55) © 2011 by the American
College of Cardiology Foundation
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248The use of drug-eluting stents (DES) results in reduced
in-stent restenosis and target lesion revascularization com-
pared with bare-metal stents (BMS) (1–3). Significant
clinical issues remain, including delayed arterial healing,
impaired re-endothelialization, prolonged requirement for
dual antiplatelet therapy, as well as late and very late stent
thrombosis (4–7). This has influenced clinical practice, in
that there was a 20% decline between 2006 and 2008 in the
use of DES for non–ST-segment elevation myocardial infarc-
tion patients (8).
Local drug delivery via a drug-coated balloon (DCB) has
been proposed as a potential solution to the cellular prolif-
erative response stimulated by the implantation of stents.
Delivery of an antiproliferative drug, which could achieve
maximal concentration of therapeutic bioactive agent within
the stented arterial wall, might minimize systemic side
effects, reduce drug-artery exposure time, obviate the need
for polymer coating on stents, and circumvent the compli-
cations of DES.
Paclitaxel is a lipophilic drug,
which allows retention in the ar-
tery wall and rapid cellular uptake
despite short exposure duration
(9). It suppresses proliferation and
migration by inhibition of micro-
tubular disassembly and cellular
function (10–13). Therefore, pa-
clitaxel is a candidate for use on
DCBs. Pre-clinical evaluation
(14) and clinical trials have dem-
onstrated that paclitaxel-coated
balloons (PCB) can provide ade-
quate drug concentration in the
artery wall and reduce neointimal
growth with continued benefit for
p to 2 years (15–18).
Several studies have demonstrated abnormal vasomotor
unction after first-generation DES 6 to 12 months after
mplantation (19–23). These effects have been attributed to
ocal toxicity, inflammation, delayed healing, and oxidative
tress. Vasomotor function after PCB administration has
ot been evaluated. We therefore investigated endothelial-
ependent and -independent vasomotion after PCB treat-
ent in a porcine coronary BMS model.
ethods
Study devices. The SeQuent Please (B. Braun Melsungen
G, Berlin, Germany) PCB was used for local delivery of
aclitaxel. It was formulated with 3 g/mm2 of paclitaxel
film, with iopromide as a hydrophilic spacer, on a total
balloon length of 17 mm. Previously published animal data




BMS  bare-metal stent(s)
D1  diameter of segment
5 to 10 mm distal to stent
D2  diameter of segment
10 to 15 mm distal to stent
DCB  drug-coated
balloon(s)
DES  drug-eluting stent(s)
INTG  nitroglycerin
PCB  paclitaxel-coated
balloon(s)arterial wall with balloon inflation (24). The non-DCB(Powersail RX, length 17 mm, Abbott Vascular, Redwood
City, California) and the BMS (MULTI-LINK VISION,
length 15 mm, Abbott Vascular) were commercially
purchased.
Experimental design. Animal handling and care followed the
recommendations of the National Institute of Health guide for
care, and use of laboratory animals was consistent with guide-
lines of the American Heart Association. All protocols were
approved by the Animal Care and Use Committee and were
consistent with Association for Assessment and Accreditation
of Laboratory Animal Care guidelines.
Eighteen Yorkshire farm pigs (33.6  3.1 kg) were
enrolled in this study. The 13 animals that underwent
coronary stent implantation received a combination of 81
mg of aspirin and 75 mg of clopidogrel by mouth daily,
which started 3 days before stent implantation and contin-
ued until termination. All pigs were fasted overnight before
procedures. The animals were sedated with an intramuscu-
lar injection of ketamine 20 mg/kg, xylazine 2 mg/kg, and
atropine 0.05 mg/kg. After intubation, general anesthesia
was induced and maintained with isoflurane (2.5%). Elec-
trocardiographic and blood pressure monitoring were per-
formed throughout the procedures.
Per standard protocol of our group (25), after full hepa-
rinization (200 U/kg), cardiac catheterization and stents
were implanted. Quantitative coronary angiography guid-
ance was used to obtain a stent-to-artery diameter ratio of
1.1:1. Thirteen pigs underwent BMS implantation followed
by post-dilation with either PCB (arteries, n  17) or
conventional non-DCB (arteries, n 13). Not all arteries in
all pigs were used, due to lack of appropriately sized arterial
segments to achieve the specified stent-to-artery ratios, or
due to lack of an adequate length of distal bed to perform
vasomotion testing. The balloon-to-artery diameter ratio
was 1.2:1, and the inflation time was 30 s, which was within
the manufacturer’s suggested duration range. Both PCB and
non-DCB were slightly longer than the stents (2 mm) to
ensure complete coverage of the entire stented segment. To
obtain valid information, animals were randomized to bal-
loon type, and each pig was treated with only 1 type of
balloon. The remaining 5 animals (arteries, n  14) were
used for naive controls, and only vasomotor function testing
was performed at 28 days.
At 1 month, endothelium-dependent coronary vasomotor
function was assessed after infusion of incremental acetyl-
choline (Ach) doses (107 and 106 mol/l/ml) and nitro-
lycerin (NTG) (200 g). After engagement of a 6-F
coronary guide catheter, a 2.3-F infusion catheter (Ultra-
Fuse, Boston Scientific, Natick, Massachusetts) was ad-
vanced into the proximal portion of the stented artery. After
baseline angiography, Ach was infused at 1 ml/min for 2
min, with precisely 5-min intervals between each injection.
The same volume was injected for each Ach administration.
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249sion by a single angiographer with consistent hand-contrast
injection via a 10-ml syringe. Endothelium-independent
function analysis was assessed by a bolus injection of
intracoronary NTG. The animals were then terminated for
complete histopathological evaluation.
Quantitative coronary angiography. Coronary angiography
as performed using a digital X-ray system (Allura FD10,
hilips, Amsterdam, the Netherlands) in monoplane pro-
ections at 15 frames/s. The monoplane view selected
rovided a clear visualization of the entire target artery. The
istance from the animal to the image intensifier was kept at
ts closest position. Offline quantitative coronary measure-
ents were performed using a computer-based system
Xper, Philips, Amsterdam, the Netherlands) by an inde-
endent unbiased observer, blinded to study assignment.
he mean luminal diameters of 5-mm segment lengths
ere calculated between 2 locations distal to the stent: 5 to
0 mm (D1) and 10 to 15 mm (D2). Each segment was
eferenced to a specific anatomic landmark for identifica-
ion. Camera angles were kept the same at baseline and
ollow-up angiography. All measurements were obtained
uring diastole. Responses of the luminal diameters to
nfusions of Ach and NTG were expressed as percentages of
iameter changes from the baseline before infusion.
Angiographic measurements for target artery diameter
nd post-stent and balloon minimal lumen diameter were
easured immediately after implantation. Reference artery
iameter was obtained by an interpolated method. The
inimal lumen diameter, late lumen loss, and percentage of
iameter in-stent stenosis were measured at 1-month
ollow-up. Late lumen loss was calculated as the difference
etween post-intervention and follow-up minimal lumen
iameter.
Histomorphometry and histopathology. At explantation,
the hearts were rinsed with 0.9% NaCl solution, and
perfusion fixed with a mixture of buffered 1.25% glutaral-
dehyde/5% formalin at approximately 100-mm Hg pressure
for 15 min, and then immersed in formalin overnight. The
subsequent day, the coronary arteries were excised with a
small rim of adjacent myocardium and adipose tissue.
Stented arterial segments were dehydrated in graded etha-
nol series to 100%, and then embedded in methyl methac-
rylate resin. Sections from the proximal, middle, and distal
stent regions were cut using a heavy-duty microtome
equipped with a tungsten-carbide knife, and mounted on
glass slides. The immediate proximal and distal segments
adjacent to the stented artery were embedded in paraffin. All
slices were stained with hematoxylin-eosin and Movat
pentachrome and analyzed using a computer-assisted image
analysis system (Image-Pro Plus, Media Cybernetics, Silver
Spring, Maryland).
Each artery section was imaged using a charge-coupled
device–imaging camera at an appropriate low magnification.
Morphometric analysis was performed by computerizedplanimetry using Image-Pro Plus software on proximal,
mid, and distal sections cut from each stented artery. The
lumen, internal elastic lamina, and external elastic lamina
were traced and area measurements obtained; the areas of
the neointima and tunica media were obtained by subtrac-
tion of the lumen from the internal elastic lamina and
internal elastic lamina from external elastic lamina, respec-
tively. The neointimal thickness at each stent strut site was
also measured. The histological percentage of area stenosis
[% area stenosis (1 [luminal area/internal elastic lamina
area])  100] was then calculated. We also measured the
“gap width,” which was defined as the perpendicular dis-
tance (in millimeters) between the strut and internal elastic
lamina, as an index of stent malapposition.
Each stent strut was scored for inflammation, intramural
thrombus, and luminal thrombus by using hematoxylin-
eosin stained sections. Inflammation score was assigned
according to the following semiquantitative grading scale:
0  none; 1  mild (scattered inflammatory cells); 2 
oderate (localized, moderate to dense cellular aggregate
urrounding the strut noncircumferentially); and 3  severe
circumferential dense lymphohistiocytic cell infiltration)
ccording to previously published methods (26). Figure 1
llustrates the inflammation score in detail. Intramural
hrombi and luminal thrombi were scored according to a
imilar grading scale of 0 to 3. Re-endothelialization was
cored by the circumferential extent of luminal surface
overage in each section with flattened, confluent endothe-
ial or endothelial-like cells as follows: 0 0% to 25% coverage
of circumference; 1 25% to 50% coverage; 2 50% to 75%
coverage; and 3  75% to 100% coverage.
Statistical analysis. All results are presented as mean  SD
unless otherwise indicated. Statistical analysis was performed
by Sigma STAT (version 3.5, Systat Software, Inc., Erkrath,
Germany) and Stata (version 10.0, StataCorp, College Station,
Texas). Angiographic data, histomorphometric data, and his-
tophathological data were evaluated by Student unpaired t test.
The assessment of correlation of histological inflammation
scores with vascular response to Ach at different locations was
performed by linear regression analysis. The mean values of
coronary vasomotor responses between 2 groups were com-
pared using 2-way analysis of variance followed by post-hoc
testing with Sheffe test. A p value 0.05 was considered
significant. Measurements of the percentage changes in coro-
nary diameter in response to Ach (107 mol/l/ml) from
baseline values by the 2 independent observers were highly
reproducible (r  0.96, p  0.0001).
Results
All animals tolerated the procedures without change in hemo-
dynamic parameters, and there were no complications or
mortalities. All stented arteries were angiographically patent
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250Baseline and follow-up angiographic characteristics. Illus-
rative examples of angiography at pre-stent baseline, post-
alloon dilation, and 28-day follow-up for PCB and non-
CB groups are shown in Figure 2. Segments D1 and D2
argeted for vasomotor function analysis are indicated.
here were no differences between PCB and non-DCB in
aseline target artery diameter (2.60 0.13 mm and 2.62
.13 mm, p 0.69). The pressures for deployment of stents
nd for balloon inflations were similar between groups (stent
eployment: PCB: 10.2  1.0 atm, non-DCB: 10.2  1.1
atm; and balloon inflation: PCB: 9.2  2.9 atm, non-DCB:
7.9  3.5 atm; p  NS, respectively). After implantation,
he coronary blood flow appeared normal with brisk ante-
rade flow and was unchanged from baseline for all im-
lanted arteries. The minimal lumen diameter at follow-up
as similar between PCB and non-DCB (2.13  0.42 mm
nd 2.00  0.33 mm, p  0.35). Angiographic late lumen
as also similar for PCB and non-DCB (0.29  0.41 mm
nd 0.42 0.37 mm, p 0.38). The percentages of diameter
Figure 1. Histopathological Inflammatory Reaction Was Determined by Sco
The inﬂammation score at each strut for paclitaxel-coated balloon (PCB) (A) an
high (100) light microscopic magniﬁcation.tenosis at 28-day follow-up for PCB and non-DCB werelike (13.4 11.6% for PCB, and 15.6 6.7% for non-DCB,
 0.54).
Coronary endothelial function after balloon post-dilation. The
baseline arterial diameter pre-Ach infusion was similar
among the PCB, non-DCB, and naive groups at both distal
locations: D1 (2.15  0.23 mm, 2.11  0.11 mm, and
2.12  0.25 mm; p  0.25) and D2 (1.97  0.17 mm,
1.84  0.29 mm, and 1.90  0.28 mm; p  0.39). The
degree of vasodilatory response to Ach, expressed as per-
centage of diameter change, was significantly diminished in
PCB-treated arteries, compared with non-DCB and naive
arteries. There were no differences between non-DCB and
naive responses (p 0.87 for D1 and p 0.93 for D2). The
percentage of diameter changes in response to Ach 107
mol/l/ml at D1 and D2 were 2.96  4.03% and 2.65 
5.45% for PCB; 7.16  6.30% and 9.19  7.94% for
non-DCB; 6.83  3.11% and 8.70  2.86% for naive
rteries (p  0.05 PCB vs. non-DCB and naive, respec-
tively). A similar pattern was observed for Ach 106
f Hematoxylin-Eosin Stained Sections
–drug-coated balloon (non-DCB) (B) are demonstrated, using low (20) andring o
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2519.49  8.56% and 9.09  6.67% for non-DCB; and 9.20 
1.73% and 9.93  4.09% for naive [p  0.05 PCB vs.
on-DCB and naive, respectively]). However, NTG-induced
ndothelium-independent vasorelaxation was comparable
mong PCB, non-DCB, and naive arteries at both D1 and D2
p  NS). The vascular responses to Ach and NTG were not
ifferent between locations D1 and D2 in each group. Figure 3
llustrates the diameter changes in response to Ach or NTG at
1 and D2 sites in all 3 groups.
Histopathological and histomorphometric analysis. Both the
CB and non-DCB groups demonstrated thin fibrocellular
eointimal formation in the stented artery segments. There
ere no luminal thrombi present in any specimen. However,
he PCB, but not the non-DCB, arteries were characterized
y a toxic reaction surrounding the stent struts, including
nflammatory cell infiltration, substantial fibrin deposits,
nd peristrut amorphous material. Figures 4A and 4B
llustrate the microscopic appearance of the coronary artery
all for each of the balloon types.
In accordance with the angiographic data, there were no
ifferences between the groups for neointimal growth,
ncluding intimal thickness and cross-sectional area. The
ercentage of cross-sectional area stenosis of the lumen by
Figure 2. Angiography at Pre-Stent Implantation, Post-Balloon Dilation, and
(A) The PCB group; (B) the non-DCB group. The red arrows show stented seg
(D1) and 10 to 15 mm (D2), indicated by yellow arrows. Abbreviations as in Feointima was 26.43  10.27% for PCB versus 22.23 .04% for non-DCB (p  0.22). Table 1 summarizes the
istomorphometric measurements.
Histopathologic analysis revealed significantly higher in-
ammation scores for PCB compared with non-DCB
1.72  0.33 vs. 1.26  0.32, p  0.001) and greater
intramural thrombus scores (1.71  0.39 vs. 0.90  0.38,
 0.001). Inflammation scoring of all examined sections
at 1 month for PCB and non-DCB, respectively, revealed:
51% and 83% with grade 1 inflammation, 25% and 15%
with grade 2, and 24% and 2% with grade 3. On histological
sections, stent malapposition was assessed as a gap between
stent strut and internal elastic lamina. A gap was significantly
less frequently observed in non-DCB compared with PCB
(1.7% vs. 41.6%, p  0.0001). When present, the width of
these gaps was dramatically less for non-DCB (0.05  0.01
mm) compared with PCB (0.11  0.01 mm; p  0.0001).
All the stent struts appeared to be covered by a confluent
endothelial-like cell lining. The nonstented proximal and distal
coronary segments were evaluated by hematoxylin-eosin, and
no structural abnormalities were seen at these locations.
Figure 5 shows the linear regression analysis for the
relationship of histopathology inflammatory score and va-
somotor function. The average inflammatory score per stent
w-Up at 28 Days for PCB and Non-DCB Groups
. Vasodilatory responses were measured over distal segments 5 to 10 mm
1.Follo
mentswas calculated as the sum of inflammatory score at each
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 2 , 2 0 1 1
F E B R U A R Y 2 0 1 1 : 2 4 7 – 5 5
Nakamura et al.
Paclitaxel-Coating Balloon and Vasomotion
252stent strut for 3 sections (proximal, mid, and distal), and
divided by the number of struts in the examined sections. We
found that the inflammatory reaction (higher average score) in
the stented artery wall appears inversely correlated with the
percentage diameter change after Ach provocation test at both
distal locations.
Discussion
In a porcine coronary stent model, PCB after dilation was
associated with diminished endothelial-dependent vaso-
motor function in the distal coronary conduit artery,
compared with non-DCB dilation or naive arteries.
Figure 3. Comparisons of Percentage of Artery Diameter Changes at 2
Distal Locations D1 and D2 in Response to Ach
Percentages of changes in epicardial diameter from baseline to acetylcho-
line (Ach) 107 mol/l/ml, and 106 mol/l/ml, and nitroglycerin (NTG) 400
g are shown. Data are expressed as mean  SD. †p  0.05 versus non-
DCB and naive artery, *p  0.02 versus non-DCB and 0.01 versus naive.
Abbreviations as in Figures 1 and 2.Endothelial-independent vasomotion did not differ be-tween groups. In addition, PCB treatment, compared
with non-DCB, elicited greater inflammatory cell infil-
tration, fibrin deposition, and stent strut malapposition
and did not achieve inhibition of neointimal formation at
28 days. To our knowledge, this is the first evaluation of
coronary vasomotor function after PCB compared with
non-DCB and naive arteries in this model. The exact
reason for incomplete stent apposition is still not fully
clear. It has been observed because of chronic inflam-
matory response, which may be a trigger for stent
thrombosis (27). All of such findings have significant
implications for further refining this novel device,
given heightened safety concerns of future intracoronary
devices.
Although compared with BMS, DES dramatically reduce
in-stent restenosis and target lesion revascularization, sev-
eral randomized studies (7,28,29) suggest an increased risk
of late stent thrombosis/very late stent thrombosis following
DES compared with BMS. Delayed arterial healing, poor
re-endothelialization, local inflammatory reaction, incomplete
stent apposition, and endothelial dysfunction may contribute
to the pathogenesis of this phenomenon (19,22,27,30–32).
The goal of development of the DCB was to overcome the
limitations of DES while maintaining the inhibition of
restenosis. Pre-clinical and clinical studies have demon-
strated a benefit of PCB for prevention of in-stent restenosis
(15–18,33). Scheller et al. (24) have reported that PCB
decreased neointimal proliferation in a dose-dependent
manner in a porcine model. A similar reduction has been
reported by Speck et al. (34). In contrast, we did not find a
reduction in in-stent stenosis at 28 days with PCB use. Two
potential contributors to this lack of inhibition of neointi-
mal formation are that the DCB was used as a post-dilation
balloon and the duration of DCB inflation applied. Other
studies used stents that were pre-mounted on the DCB, and
the entire procedure was a single inflation (15,24). In
contrast, we deployed the PCB as a distinct post-dilation
inflation after stent implantation. The duration of DCB
balloon inflation was 30 s rather than 60 s as used in some
other studies. The impact of balloon inflation duration is
unknown. However, Cremers et al. (15) did not find any
difference in efficacy between 10-s and 60-s inflations, using
this same balloon coated with paclitaxel and a small amount
of iopromide, which improves the solubility of paclitaxel.
Once delivered, paclitaxel is a highly lipophilic drug and
persists in the arterial wall by binding to hydrophobic
arterial tissue binding sites (35). Additionally, we found
other histological effects of paclitaxel, such as increased
inflammatory response, suggesting effective vascular delivery
of paclitaxel.
We found that treatment with PCB resulted in a signif-
icantly diminished vasodilatory response to Ach provocation
compared with non-DCB treated and naive arteries. The
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253known. Inflammatory responses to treatments could play an
important role by chronic induction of reactive oxygen
species, thereby increasing cellular toxicity and impairing
nitric oxide bioavailability and bioactivity. Inflammatory
mediators may exert their effects by both diffusion and by
vasa vasorum to the distal vasculature. Vasa vasorum interna
originate directly from the arterial lumen and can extend
Figure 4. Light Microscopic Images of Coronary Arteries After PCB and No
The low magniﬁcation (20) light microscopic images (A) of Movat pentachro
groups without evidence of luminal thrombus. High magniﬁcation (100) ligh
tent strut inﬂammatory cell inﬁltration and intramural thrombi in the PCB grou
Table 1. Histomorphometric Measurement
PCB (n  17) Non-DCB (n  13) p Value
Lumen area, mm2 4.09 0.89 4.60 0.92 0.13
Stent area (IEL), mm2 5.61 0.77 5.87 0.77 0.37
EEL area, mm2 6.86 0.82 7.21 0.88 0.28
Medial area, mm2 1.25 0.20 1.34 0.26 0.31
Intimal thickness, mm 0.17 0.10 0.15 0.05 0.34
Neo-intimal area, mm2 1.53 0.64 1.27 0.30 0.20
% Area stenosis 26.43 10.27 22.23 7.04 0.22pEEL external elastic lamina; IEL internal elastic lamina.over several centimeters along the coronary artery wall (36).
We have previously demonstrated that the localized surface
inflammatory response to overlapping paclitaxel-eluting
stented segments was associated with vasomotor dysfunc-
tion in a porcine coronary model. In addition, superoxide
anion (O2
) production was significantly increased at these
same sites (37). Consistent with this hypothesis, we found
an inverse relationship between histopathologic inflamma-
tion score at the stented segment and distal coronary
vasomotor function. These findings may suggest that vas-
cular inflammation in response to PCB may play a role in
downstream endothelial dysfunction.
Study limitations. A relatively small number of animals were
sed in this study, and the statistical analysis of the data
hould be viewed accordingly. We chose a large animal
odel, the most similar to human coronary anatomy and
hysiology. However, it does not precisely replicate human
therosclerotic disease states. Furthermore, we did not
onduct time course studies, which would have addressed
After Dilation
ained sections demonstrate a thin ﬁbrocellular neointimal formation in both
oscopic images (B) of hematoxylin-eosin stained sections demonstrate peris-
not in the non-DCB group. Abbreviations as in Figures 1, 2, and 3.n-DCB
me–st
t microtential endothelial functional recovery at later time points.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 2 , 2 0 1 1
F E B R U A R Y 2 0 1 1 : 2 4 7 – 5 5
Nakamura et al.
Paclitaxel-Coating Balloon and Vasomotion
254Finally, we did not perform a pharmacokinetics study because
the PCB was purchased as a commercial product.
Conclusions
Treatment with PCB immediately after stent implantation
was associated with attenuated vasodilatory response to Ach
in the distal and far distal nonstented segments compared
with non-DCB and naive arterial controls. There were no
beneficial effects of the PCB on neointimal suppression at 1
month in this porcine model. An increased inflammatory
reaction within the treated stented segments may contribute
to this distal vasomotor dysfunction.
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